The scrip plummeted by 13.45 per cent to Rs 1,294.05, its 52-week low, on BSE.
On NSE, shares of the company tanked 14.38 per cent to hit its one-year low of Rs 1,280.
The counter was the worst performer among the blue-chips on both Sensex and Nifty.
At present, the company has a market valuation of Rs 62,227.76 crore.
Meanwhile, BSE has sought clarification from Lupin with reference to the news about Mandideep unit, inspected by the USFDA from February 8-19, 2016, and that the observations are serious in nature.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
